Abstract
Vitamin D deficiency is common in critically ill patients and associated with increased mortality, as well as an increased risk of acute kidney injury. The occurrence of acute kidney injury by itself substantially increases critical care mortality. In addition to regulating calcium and phosphorus homeostasis and bone metabolism, vitamin D has pleotropic effects on the immune response. Potential mechanisms of how a deficiency in vitamin D could predispose individuals to increased risk of acute renal failure include dysregulation of the immune system, predisposing patients to sepsis, endothelial dysfunction and prevention of healing of renal ischemia-reperfusion injury. Toll-like receptors, NF-κB and the renin-angiotensin-aldosterone system are mediators of vitamin D effects.
Keywords: Acute kidney injury, critical care mortality, ICU, vitamin D.
Inflammation & Allergy - Drug Targets (Discontinued)
Title:Vitamin D in Acute Kidney Injury
Volume: 12 Issue: 4
Author(s): Andrea B. Braun and Kenneth B. Christopher
Affiliation:
Keywords: Acute kidney injury, critical care mortality, ICU, vitamin D.
Abstract: Vitamin D deficiency is common in critically ill patients and associated with increased mortality, as well as an increased risk of acute kidney injury. The occurrence of acute kidney injury by itself substantially increases critical care mortality. In addition to regulating calcium and phosphorus homeostasis and bone metabolism, vitamin D has pleotropic effects on the immune response. Potential mechanisms of how a deficiency in vitamin D could predispose individuals to increased risk of acute renal failure include dysregulation of the immune system, predisposing patients to sepsis, endothelial dysfunction and prevention of healing of renal ischemia-reperfusion injury. Toll-like receptors, NF-κB and the renin-angiotensin-aldosterone system are mediators of vitamin D effects.
Export Options
About this article
Cite this article as:
Braun B. Andrea and Christopher B. Kenneth, Vitamin D in Acute Kidney Injury, Inflammation & Allergy - Drug Targets (Discontinued) 2013; 12 (4) . https://dx.doi.org/10.2174/18715281113129990044
DOI https://dx.doi.org/10.2174/18715281113129990044 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
ATP-Sensitive K+ Channels: Current and Putative Target for the Prevention and Treatment of Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Coronary Collateral Circulation in Man
Current Cardiology Reviews Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design Anti-Oxidant
Current Bioactive Compounds Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Multi-Target Strategy and Experimental Studies of Traditional Chinese Medicine for Alzheimer’s Disease Therapy
Current Topics in Medicinal Chemistry Cerebral Microbleeds Do Not Predict Hemorrhagic Transformation in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Contribution of Canalicular Glutathione Efflux to Bile Formation. From Cholestasis Associated Alterations to Pharmacological Intervention to Modify Bile Flow
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design